Mayne Pharma Group Stock Price To Book

MAYNFDelisted Stock  USD 0.13  0.00  0.00%   
Mayne Pharma Group fundamentals help investors to digest information that contributes to Mayne Pharma's financial success or failures. It also enables traders to predict the movement of Mayne Pink Sheet. The fundamental analysis module provides a way to measure Mayne Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mayne Pharma pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Mayne Pharma Group Company Price To Book Analysis

Mayne Pharma's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

 = 

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Mayne Pharma Price To Book

    
  0.73 X  
Most of Mayne Pharma's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mayne Pharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition

Based on the latest financial disclosure, Mayne Pharma Group has a Price To Book of 0.7261 times. This is 97.17% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to book for all United States stocks is 92.36% higher than that of the company.

Mayne Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mayne Pharma's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mayne Pharma could also be used in its relative valuation, which is a method of valuing Mayne Pharma by comparing valuation metrics of similar companies.
Mayne Pharma is currently under evaluation in price to book category among related companies.

Mayne Fundamentals

About Mayne Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mayne Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mayne Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mayne Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Consideration for investing in Mayne Pink Sheet

If you are still planning to invest in Mayne Pharma Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mayne Pharma's history and understand the potential risks before investing.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets